Baxter Seeks Unusual Second 30-Month Stay On Generic Version Of Its Anesthetic Suprane
This article was originally published in The Pink Sheet Daily
Executive Summary
A redesign of the proposed generic and changes to the Paragraph IV certification could give the brand an additional six-month hold on approval of the ANDA.